UNDERTAKE ACTIVITIES TO IMPROVE INITIAL MEASUREMENT COMPONENT PERCENTAGES Sample Clauses

UNDERTAKE ACTIVITIES TO IMPROVE INITIAL MEASUREMENT COMPONENT PERCENTAGES. ALLTEL and Client shall mutually agree to undertake quality improvement tasks intended to improve the initial Measurement Component Percentages established based on integration test results. ALLTEL and Client shall establish testing targets for mock conversion testing based on the anticipated results of those quality improvement tasks. Quantity improvement tasks may include the following: - Modification to programming conversion algorithms performed by ALLTEL; - Table corrections performed by ALLTEL or Client; - Data clean-up performed by Client; - Data cleansing performed by ALLTEL. Each quality improvement task will be assigned to either ALLTEL or Client and will be documented by ALLTEL. For example, a programmatic change which may improve the initial Measurement Criteria Percentage for the Measurement Component CAMS Customer Entities may be identified with the anticipated percentage increase in the Measurement Criteria Percentage for that Measurement Component of five percent (5%). ALLTEL and Client would mutually agree that such task would be assigned to ALLTEL. with the anticipation that the Measurement Criteria Percentage for that Measurement Component against which ALLTEL will be measured following Conversion would be increased as a result of the successful completion of the assigned task. ALLTEL will be held accountable only for the task assigned to ALLTEL. If Client does not timely perform tasks assigned to Client, Measurement Component Percentage would not be increased for that Measurement Component to the extent expected as related to those tasks.
AutoNDA by SimpleDocs

Related to UNDERTAKE ACTIVITIES TO IMPROVE INITIAL MEASUREMENT COMPONENT PERCENTAGES

  • Development Activities NovaDel shall not be required to commence any Development Activities until Licensee has paid at least twenty-five percent (25%) of the non-refundable License Fee described in Section 4.4.

  • Research Program Funding 3.1.1 Pfizer will fund the research to be performed by Rigel, pursuant to the Agreement, according to the following schedule: COMMITMENT YEAR ANNUAL COMMITMENT 1 $2,350,000.00 2 $2,350,000.00 The funding payments of two million three hundred and fifty thousand dollars ($2,350,000.00) shall support the work of the equivalent of ten (10) full time employees ("FTEs") of Rigel.

  • Commercialization Activities Within North America, the Parties will use Commercially Reasonable Efforts to Commercialize Licensed Products in the Field. In addition, within North America and subject to Section 2.7.6, the Parties will use Commercially Reasonable Efforts to conduct the Commercialization activities assigned to them pursuant to the Commercialization Plan/Budget, including the performance of detailing in accordance therewith. In conducting the Commercialization activities, the Parties will comply with all Applicable Laws, applicable industry professional standards and compliance policies of Celgene which have been previously furnished to Acceleron, as the same may be updated from time to time and provided to Acceleron. Neither Party shall make any claims or statements with respect to the Licensed Products that are not strictly consistent with the product labeling and the sales and marketing materials approved for use pursuant to the Commercialization Plan/Budget.

  • Market Activities The Company will not, directly or indirectly, (i) take any action designed to cause or result in, or that constitutes or would reasonably be expected to constitute, the stabilization or manipulation of the price of any security of the Company to facilitate the sale or resale of Common Stock or (ii) sell, bid for, or purchase Common Stock in violation of Regulation M, or pay anyone any compensation for soliciting purchases of the Placement Shares other than the Agent.

  • Permitted Activities The Executive shall devote his entire business time, attention and energies to the Business of the Employer and shall not during the Term be engaged (whether or not during normal business hours) in any other business or professional activity, whether or not such activity is pursued for gain, profit or other pecuniary advantage; but this shall not be construed as preventing the Executive from:

  • Development Program A. Development Activities to be Undertaken (Please break activities into subunits with the date of completion of major milestones)

  • Commercialization Efforts The RECIPIENT shall, including whether through its own efforts or the efforts of a licensee under a License Agreement allowed by the terms of this Attachment, use diligent and commercially reasonable efforts to commercialize at least one Commercial Product or Commercial Service or otherwise bring to practical application the Project Results in accordance with the commercial development plan submitted with the Application and including any changes to such commercial development plan in accordance with Section D3.01. For the avoidance of doubt, partnering or licensing activities shall be considered to be efforts to commercialize.

  • Research Plan The Parties recognize that the Research Plan describes the collaborative research and development activities they will undertake and that interim research goals set forth in the Research Plan are good faith guidelines. Should events occur that require modification of these goals, then by mutual agreement the Parties can modify them through an amendment, according to Paragraph 13.6.

  • Research Plans The Research Plan for the [***] Designated Target is attached as Schedule 2.2.3-1. Subsequent Research Plans agreed upon in accordance with Section 2.4.2.4 will be attached as additional sequentially numbered schedules (Schedule 2.2.3-2, Schedule 2.2.3-3, etc.).

  • Information Systems Acquisition Development and Maintenance a. Client Data – Client Data will only be used by State Street for the purposes specified in this Agreement.

Time is Money Join Law Insider Premium to draft better contracts faster.